{"id":2504,"date":"2021-03-19T11:20:00","date_gmt":"2021-03-19T10:20:00","guid":{"rendered":"https:\/\/www.corsiaffariregolatori.it\/it\/?p=2504"},"modified":"2022-02-03T11:23:57","modified_gmt":"2022-02-03T10:23:57","slug":"clinical-trials-2017-745","status":"publish","type":"post","link":"https:\/\/www.direnzo.biz\/it\/clinical-trials-2017-745\/","title":{"rendered":"Clinical trials of medical devices in the European Regulation 2017\/745"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">On 11 March 2021 Di Renzo Regulatory Affairs attended a digital event on&nbsp;<a href=\"https:\/\/www.direnzo.biz\/it\/en\/medical-devices-consulting\/clinical-trial-medical-device\/\">clinical trials with medical devices<\/a>, and the impact with&nbsp;<strong>Regulation EU 2017\/745<\/strong>. The event was organised by the Italian Pharmaceutical Industry Association (<a href=\"https:\/\/www.afiscientifica.it\/\" target=\"_blank\" rel=\"noreferrer noopener\">Associazione Farmaceutici Industria, AFI<\/a>) in collaboration with the University of Milan, and was an occasion to share the analysis of the challenges that Medical Device (MD) manufacturers shall face in the light of the new provisions of the Regulation in terms of clinical evaluation as well of clinical trials.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The new rules, whose implementation is&nbsp;<strong>scheduled on May 2021<\/strong>, provides for increased levels of care regarding the safety and efficacy of medical devices. From this point of view, the Regulation attributes to manufacturers the&nbsp;<strong>responsibility to control<\/strong>&nbsp;the device\u2019s design, manufacturing and marketing. These are aspects that the past Directive mentioned with no special depth, and that manufacturers are now forced to address.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Regulation, in fact, imposes a more systematic and stricter approach compared to the Directive, that translates however into a greater commitment by the companies in terms of time and costs. A particularly relevant point is the&nbsp;<strong>transition to the new norm<\/strong>, implying the review of the company procedures (gap analysis), especially for&nbsp;<a href=\"https:\/\/www.direnzo.biz\/it\/en\/medical-devices-consulting\/ce-certification\/\">MDs that are already CE marked<\/a>, and that will be reclassified according to the Regulation. Moreover, the demonstration of the concept of equivalence will not be so easily&nbsp;<strong>applicable with the Regulation<\/strong>, requiring that the equivalence is demonstrated based on strong scientific grounds, including relevant clinical data. These points, all together, will lead to an increase of&nbsp;<strong>clinical trial applications for medical devices<\/strong>&nbsp;and, consequently, to a need to implement the legislation process and the level of collaboration between companies, Sponsors\/Manufacturers and Ethics Committees.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"clinical-evaluation\">Clinical evaluation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Regulation provides for that, in order to obtain the conformity to the essential requirements of safety and performance, manufacturing companies should carry out a clinical assessment of the available data, and in case, if the data are not sufficient, to proceed to a clinical investigation. Art. 61 defines in few points the ultimate purpose of the&nbsp;<strong>clinical evaluation<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Confirm the compliance with the pertinent safety requirements<\/li><li>Confirm the performance of the medical device<\/li><li>Assess side effects<\/li><li>Assess the acceptability of the risk\/benefit profile<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">As the clinical data used to obtain or confirm the above should provide sufficient clinical evidence, and the level of such evidence should be appropriate considering the technical characteristics of the device, it becomes necessary for the manufacturer to prepare an assessment and investigation plan ensuring suitable controls throughout the whole life cycle of the medical device via the introduction of traceability systems and the drafting of the PMCF.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-clinical-investigation\">The clinical investigation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Given the importance of the continuous clinical assessment process, the clinical investigation will acquire an essential relevance both to&nbsp;<strong>obtain the CE marking<\/strong>, especially for implantable and class III devices (pre-marketing investigation) and to confirm the data on the use of implantable devices, also when included in the normal clinical practice (post-marketing investigations and observational studies). The clinical investigation is not always mandatory. Except for class III and implantable medical devices, for which the Regulation&nbsp;<strong>obligates the manufacturer<\/strong>&nbsp;to manage a clinical trial (except for some specific cases), for the other devices it should be carried out in case the clinical data available (scientific literature, PMS or PMCF) are not sufficient to ensure one or more safety or performance essential requirements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"post-marketing-surveillance\">Post-marketing surveillance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">With the application of the Regulation, the marketing of the product is integral part of the life cycle of the device, giving more relevance to the&nbsp;<a href=\"https:\/\/www.direnzo.biz\/it\/en\/medical-devices-consulting\/devices-vigilance\/\">post-marketing surveillance<\/a>&nbsp;(PMS). It is also provided for that manufacturers shall draft a plan and a post-marketing surveillance report. The PMS report, provided for class I MDs, and the PSUR (periodic safety update report), provided for the MDs of higher class, should always be integral part of the technical documentation, and are essential to extrapolate always updated clinical data. The post-market clinical follow-up (PMCF) is also part of the PMS: this is a continuous process aiming at integrating the collected evidence during the pre-market phase, reinforcing the data regarding the safety and efficacy of the medical device already in use.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Di Renzo Regulatory Affairs can support companies in this delicate transition phase. Thanks to the competence of experts in this sector, we can offer assistance in the different design and post-market steps of a medical device, preparing the required documentation, carrying out the PMS activities according the Regulation and supporting the interfacing with clinical sites, notified bodies and ethics committees.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Written by: Sofia Tabacco<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Foto di\u00a0Myriams-Fotos\u00a0da\u00a0Pixabay\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 11 March 2021 Di Renzo Regulatory Affairs attended a digital event on&nbsp;clinical trials with medical devices, and the impact with&nbsp;Regulation EU 2017\/745. The event was organised by the Italian Pharmaceutical Industry Association (Associazione Farmaceutici Industria, AFI) in collaboration with the University of Milan, and was an occasion to share the analysis of the challenges<br \/><a class=\"moretag\" href=\"https:\/\/www.direnzo.biz\/it\/clinical-trials-2017-745\/\">+ Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":2502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-2504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts\/2504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/comments?post=2504"}],"version-history":[{"count":0,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts\/2504\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/media\/2502"}],"wp:attachment":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/media?parent=2504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/categories?post=2504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/tags?post=2504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}